Kolexia
Ducreux Michel Gastro-entérologie
Ducreux Michel
Gastro-entérologie
Gustave-Roussy
Villejuif, France
697 Activités
4.8 K Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs colorectales Métastase tumorale Carcinomes Tumeurs du pancréas Tumeurs du foie Adénocarcinome Carcinome hépatocellulaire Tumeurs neuroendocrines Tumeurs gastro-intestinales

Collaborateurs

Voir plus
Boige Valerie
Boige Valerie
Gustave-Roussy, Villejuif, France
Malka David
Malka David
Gustave-Roussy, Villejuif, France
Goere Diane
Goere Diane
Hôpital Saint-Louis, Paris, France
Hollebecque Antoine
Hollebecque Antoine
Gustave-Roussy, Villejuif, France

Industries

Voir plus
Servier
16 collaboration(s)
Dernière en 2023
Roche
15 collaboration(s)
Dernière en 2023
Bayer
12 collaboration(s)
Dernière en 2023
MSD
10 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Essai Clinique (National Cancer Institute)   20 mars 2024
HERIZON-BTC-01: A Phase 2b, Open-label, Single-arm Study of ZW25 Monotherapy in Subjects With Advanced or Metastatic HER2-amplified Biliary Tract Cancers
Essai Clinique (Jazz Pharmaceuticals)   11 mars 2024
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery: A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
Essai Clinique (National Cancer Institute)   08 mars 2024
Codon-specific KRAS mutations predict survival in advanced pancreatic cancer
ESMO Gastrointestinal Oncology   01 mars 2024
Pancreatic adenocarcinoma third line systemic treatments: a retrospective cohort study.
BMC cancer   26 février 2024
BETTER2: Randomized Phase 2 Trial Of Two Chemotherapy Regimens Plus Or Minus Bevacizumab In Patients With Well Differentiated Pancreatic Neuroendocrine Tumors
Essai Clinique (Gustave-Roussy)   07 février 2024
A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer: A Randomized Phase 2 Study of Ompenaclid Versus Placebo in Combination With FOLFIRI Plus Bevacizumab in Patients With Previously Treated RAS Mutant Advanced or Metastatic Colorectal Cancer
Essai Clinique (Inspirna, Inc.)   17 janvier 2024
NEOPAN: A Randomized Phase III Trial Comparing Chemotherapy With Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma
Essai Clinique (Unicancer)   08 janvier 2024
Molecular profiling of biliary tract cancers reveals distinct genomic landscapes between circulating and tissue tumor DNA.
Experimental hematology & oncology   08 janvier 2024
Precision medicine for KRAS wild-type pancreatic adenocarcinomas.
European journal of cancer (Oxford, England : 1990)   15 décembre 2023